CJC-1295 Dosage: Doses Studied, Units and Chart
What doses of CJC-1295 have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 3 studies
- with a stated dose, listed below
- Frequency
- Varies by study
- as used in studies
- Half-life
- Not found
- No published half-life found (PubMed search, 11 Oct 2026)
- Vial sizes sold
- 2 mg, 5 mg, 10 mg
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| Four ascending single doses (first study); two or three weekly or biweekly doses (second study) | single, weekly or biweekly · subcutaneous · 28 and 49 days | Human RCT | The Journal of clinical endocrinology and metabolism 2006, PMID 16352683 |
| 60 or 90 microg/kg CJC-1295 (single injection) | single · injection (route not stated in abstract) · 1 wk to follow-up | Human uncontrolled trial | The Journal of clinical endocrinology and metabolism 2006, PMID 17018654 |
| 2 microg CJC-1295 | every 24, 48 or 72 h · not stated · 5 wk | Animal · mouse (not a human result) | American journal of physiology. Endocrinology and metabolism 2006, PMID 16822960 |
Dose to syringe units
For a 10 mg vial mixed with 2 mL of bacteriostatic water (5 mg/mL), on a U-100 syringe. These are reference amounts for the math, not suggested doses.
- 100 mcg
- 2 u
- 200 mcg
- 4 u
- 300 mcg
- 6 u
- 500 mcg
- 10 u
- 1000 mcg
- 20 u
- 2000 mcg
- 40 u
Before anyone considers it
- CJC-1295 is not FDA approved for any use.
- Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
How the human CJC-1295 studies set dose and interval
The first human program used ascending single subcutaneous doses in one study and two or three weekly or biweekly doses in a second, in healthy adults.[3]
The authors called it safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg, and noted a cumulative effect after multiple doses.[3]
A separate study measured GH overnight before and 1 wk after an injection of either 60 or 90 microg/kg CJC-1295 in healthy 20- to 40-yr-old men.[4]
Responses to the two injection amounts did not differ significantly.[4]
Dosing interval in GHRH knockout mice
In GHRH knockout mice, the same 2 microg of CJC-1295 was given every 24, 48 or 72 h for 5 weeks. Daily dosing maintained normal body composition and growth, and the same dose was less effective every 48 or 72 h.[5]
No label exists
Drugs@FDA lists no CJC-1295 product, so no FDA label gives a dose.[9]
Common questions
How many units is 300 mcg of CJC-1295?
It depends on the water added. A 10 mg vial with 2 mL of water gives 5 mg/mL, so 300 mcg is 6 units on a U-100 syringe. Use the calculator for other mixes.
Is CJC-1295 FDA approved?
No. CJC-1295 is not FDA approved for any use.
What is the CJC-1295 DAC dosage per day?
The human studies cited gave single, weekly or biweekly injections rather than daily ones.[3]
More on CJC-1295
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
- 4Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
- 5Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
- 6PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 9Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.